Robert G. Wilcox

15.6k total citations · 4 hit papers
47 papers, 5.9k citations indexed

About

Robert G. Wilcox is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Robert G. Wilcox has authored 47 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Cardiology and Cardiovascular Medicine, 14 papers in Surgery and 8 papers in Internal Medicine. Recurrent topics in Robert G. Wilcox's work include Acute Myocardial Infarction Research (35 papers), Antiplatelet Therapy and Cardiovascular Diseases (10 papers) and Atrial Fibrillation Management and Outcomes (10 papers). Robert G. Wilcox is often cited by papers focused on Acute Myocardial Infarction Research (35 papers), Antiplatelet Therapy and Cardiovascular Diseases (10 papers) and Atrial Fibrillation Management and Outcomes (10 papers). Robert G. Wilcox collaborates with scholars based in United Kingdom, United States and Canada. Robert G. Wilcox's co-authors include Eric J. Topol, Robert A. Harrington, Allan M. Skene, Paul W. Armstrong, J R Hampton, Harvey D. White, Carl Olsson, Gorm Boje Jensen, Gerhard Von Der Lippe and A. Michael Lincoff and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Robert G. Wilcox

47 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION

1988 858 citations Robert G. Wilcox, Carl Olsson et al. The Lancet profile →
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention

2003 836 citations A. Michael Lincoff, Robert A. Harrington et al. profile →
Predictors of Outcome in Patients With Acute Coronary Syndromes Without Persistent ST-Segment Elevation

2000 716 citations Robert G. Wilcox, Robert A. Harrington et al. profile →
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

2002 650 citations Robert A. Harrington, Harvey D. White et al. The Lancet profile →

Peers

Robert G. Wilcox

CCM

SURGE

RNMI

EPIDE

Anatoly Langer Canada

Shmuel Gottlieb Israel

David J. Moliterno United States

Jean‐Philippe Collet France

Amadeo Betriu Spain

Ulrich Tebbe Germany

Yves Rosenberg United States

Cynthia D. Adams United States

Peter Sinnaeve Belgium

Jay Horrow United States

Anatoly Langer Canada

Robert G. Wilcox

4.8k ×1.0

CCM

2.2k ×1.0

SURGE

1.6k ×1.3

RNMI

1.2k ×1.0

360 ×0.9

EPIDE

Citations per year, relative to Robert G. Wilcox Robert G. Wilcox (= 1×) peers Anatoly Langer

Countries citing papers authored by Robert G. Wilcox

Since Specialization

Citations

This map shows the geographic impact of Robert G. Wilcox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert G. Wilcox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert G. Wilcox more than expected).

Fields of papers citing papers by Robert G. Wilcox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert G. Wilcox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert G. Wilcox. The network helps show where Robert G. Wilcox may publish in the future.

Co-authorship network of co-authors of Robert G. Wilcox

This figure shows the co-authorship network connecting the top 25 collaborators of Robert G. Wilcox. A scholar is included among the top collaborators of Robert G. Wilcox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert G. Wilcox. Robert G. Wilcox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baker, Jillian G. & Robert G. Wilcox. (2016). β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax. 72(3). 271–276. 50 indexed citations

Gershlick, Anthony, Cynthia M. Westerhout, Paul W. Armstrong, et al.. (2015). Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart. 101(9). 692–698. 23 indexed citations

Simes, R. John, Rachel O’Connell, Philip E. Aylward, et al.. (2010). Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal. 159(6). 988–997. 23 indexed citations

Erdmann, Erland & Robert G. Wilcox. (2007). Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. European Heart Journal. 29(1). 12–20. 59 indexed citations

Brener, Sorin J., A. Michael Lincoff, Eric Bates, et al.. (2005). The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: Insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. American Heart Journal. 150(1). 89–93. 7 indexed citations

Saw, Jacqueline, A. Michael Lincoff, Walter Desmet, et al.. (2004). Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade. Journal of the American College of Cardiology. 44(6). 1194–1199. 29 indexed citations

Menon, Venu, Robert A. Harrington, Judith S. Hochman, et al.. (2004). Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction. CHEST Journal. 126(3). 549S–575S. 59 indexed citations

Wong, Cheuk‐Kit, Harvey D. White, Robert G. Wilcox, et al.. (2003). Significance of Atrial Fibrillation During Acute Myocardial Infarction, and its Current Management: Insights from the GUSTO-3 Trial. Cardiac Electrophysiology Review. 7(3). 201–207. 48 indexed citations

Wallentin, Lars, Robert G. Wilcox, W Douglas Weaver, et al.. (2003). Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. The Lancet. 362(9386). 789–797. 263 indexed citations

10.

O’Shea, J.Conor, Robert G. Wilcox, Allan M. Skene, et al.. (2002). Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. The American Journal of Cardiology. 90(12). 1374–1377. 28 indexed citations

11.

Simes, John, Harvey D. White, Ian C. Marschner, et al.. (2002). International differences in patients, care, and outcomes associated with acute myocardial infarction: the hero-2 trial. Journal of the American College of Cardiology. 39. 280–280. 4 indexed citations

12.

Greenbaum, Adam B., Robert A. Harrington, Michael Hudson, et al.. (2001). Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. Journal of the American College of Cardiology. 37(2). 492–498. 21 indexed citations

13.

Hasdai, David, David R. Holmes, Douglas A. Criger, et al.. (2000). Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. American Heart Journal. 139(3). 454–460. 16 indexed citations

14.

Wong, Cheuk‐Kit, Harvey D. White, Robert G. Wilcox, et al.. (2000). New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience. American Heart Journal. 140(6). 878–885. 175 indexed citations

15.

Ohman, E. Magnus, Paul W. Armstrong, Harvey D. White, et al.. (1999). Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. The American Journal of Cardiology. 84(11). 1281–1286. 95 indexed citations

16.

Weaver, W. Douglas, Harvey D. White, Robert G. Wilcox, et al.. (1997). Comparisons of Characteristics and Outcomes Among Women and Men with Acute Myocardial Infarction Treated with Thrombolytic Therapy. Survey of Anesthesiology. XLI(3). 147???148–147???148. 46 indexed citations

17.

Wilcox, Robert G.. (1996). Clinical Trials in Thrombolytic Therapy: What Do They Tell Us? INJECT 6-Month Outcomes Data. The American Journal of Cardiology. 78(12). 20–23. 13 indexed citations

18.

Becker, Richard C., Andrew Charlesworth, Robert G. Wilcox, et al.. (1995). Cardiac rupture associated with thrombolytic therapy: Impact of time to treatment in the late assessment of thrombolytic efficacy (LATE) study. Journal of the American College of Cardiology. 25(5). 1063–1068. 91 indexed citations

19.

Wilcox, Robert G., Carl Olsson, Allan M. Skene, et al.. (1988). TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION. The Lancet. 332(8610). 525–530. 858 indexed citations breakdown →

20.

Wilcox, Robert G., et al.. (1979). Verification of smoking history in patients after infarction using urinary nicotine and cotinine measurements.. BMJ. 2(6197). 1026–1028. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact